Physician profile
Mark Emery
NPI 1801849674
$5,020.53
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,943 · 2020: $1,444 · 2021: $1,400 · 2022: $234.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,233.93 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $921.54 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $370.29 | 2019-2022 | |
| Genentech USA, INC. | $303.32 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $299.31 | 2020-2022 | |
| Grifols USA, LLC | $274.67 | 2019-2021 | |
| Insmed, INC. | $254.40 | 2019-2021 | |
| Genzyme Corporation | $224.82 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $164.66 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $162.34 | 2019 | |
| Mylan Specialty L.P. | $116.69 | 2019-2021 | |
| Advanced Respiratory, INC | $107.64 | 2019-2021 | |
| Circassia INC. | $94.57 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $91.56 | 2019-2021 | |
| United Therapeutics Corporation | $86.46 | 2020-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $80.85 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $74.93 | 2021-2022 | |
| Shire North American Group INC | $73.75 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $30.70 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $25.35 | 2021 | |
| Electromed, INC. | $15.43 | 2019 | |
| Astellas Pharma US INC | $13.32 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Emery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.